In India schools are open, kids are back in the schools but they are not vaccinated. The Drug Controller General of India (DCGI) is yet to approve the Covaxin rule out for children.

India: Covaxin yet to get DCGI nod for kids

India's pandemic death toll has crossed 250,000. With the risk of the third wave growing, India has now approved Covaxin trials for children between 2 to 18 years of age. Palki Sharma tells you more.

Gravitas: India to begin Covaxin vaccine trials for kids

As increasing number of state across India complain of vaccine shortage, country's Science and Technology Ministry has said that the production capacity of Covaxin will be doubled in the next one to two months (May-June).

India: Production capacity of Covaxin to be doubled by May-June 2021

<p>As part of the globalisation of India-developed COVID-19 vaccine, India's Bharat Biotech has applied for "Emergency Use Authorization" (EUA) in the Philippines. EUA was filed earlier this month in the country and is the first international regulatory filing for Bharat biotech's COVAXIN. Once approved by the local regulator, India is expected to donate some doses and open the doors for exports in commercial terms, as are being done currently by Western and Chinese vaccine manufacturers.</p>

<p>India's envoy to the Philippines Shambhu Kumaran in a tweet said, "A moment of pride for Indian R&amp;D! The first international regulatory filing for COVAXIN. Delighted it is in the Philippines, a vital Indo-Pacific partner. Process ahead will be challenging but today we celebrate those who made this key milestone possible!"</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">A moment of pride for <a href="https://twitter.com/hashtag/Indian?src=hash&amp;ref_src=twsrc%5Etfw">#Indian</a> R&amp;D! The first international regulatory filing for COVAXIN. Delighted it is in <a href="https://twitter.com/hashtag/Philippines?src=hash&amp;ref_src=twsrc%5Etfw">#Philippines</a>, a vital Indo-Pacific partner. Process ahead will be challenging but today we celebrate those who made this key milestone possible! <a href="https://twitter.com/BharatBiotech?ref_src=twsrc%5Etfw">@BharatBiotech</a> <a href="https://twitter.com/ICMRDELHI?ref_src=twsrc%5Etfw">@ICMRDELHI</a> <a href="https://t.co/CNuclsSMJN">https://t.co/CNuclsSMJN</a></p>
— Shambhu Kumaran (@shambhukumaran) <a href="https://twitter.com/shambhukumaran/status/1352223698938302464?ref_src=twsrc%5Etfw">January 21, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>The local drug regulatory authorities are looking for more clinical data from phase three trials and efficacy data. Phase III human clinical trials of COVAXIN began mid-November. The development is seen as a major step when it comes to India's vaccine exports and a boost to "Atmanirbhar Bharat" (Self-reliance).&nbsp;</p>

<p>The EUA was applied as a part of "pro-active" action and an immediate approval will be issued as soon as the data comes. A delay in such action also means an impact on commercial deals in a very competitive coronavirus vaccine market. Interestingly, the Philippines already had a deal with Novavax for coronavirus vaccines for the supply of 30 million doses commercially.&nbsp;</p>

<p>While India has so far exported India-made vaccines, the new frontier is seen when the export of India-developed vaccines becomes the norm. Meanwhile, Philippines foreign secretary Teodoro Locsin Jr has lauded India's vaccine diplomacy and, in a tweet, said, "we're looking to India to teach us. We're certainly not looking to the West. But we need to look elsewhere to teach us how to get it done"</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">We’re looking to India to teach us. We’re certainly not looking to the West. But we need to look elsewhere to teach us how to get it done. <a href="https://t.co/yXLT3kOruk">https://t.co/yXLT3kOruk</a></p>
— Teddy Locsin Jr. (@teddyboylocsin) <a href="https://twitter.com/teddyboylocsin/status/1355168310304804867?ref_src=twsrc%5Etfw">January 29, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>New Delhi has gifted India-Made COVISHIELD vaccine of Oxford-AstraZeneca, made by Serum Institute of India, to 10 countries — Bhutan, Maldives, Nepal, Bangladesh, Myanmar, Seychelles, Mauritius, Sri Lanka, Bahrain and Oman. &nbsp;</p>

<p>On Friday, Bangladesh's Foreign Secretary Ambassador Masud Bin Momen, speaking to WION, said Bharat Biotech has offered its vaccines to the country. Bangladesh is keen on the co-production of vaccines with India. Brazilian companies have also signed an agreement for the supply of COVAXIN&nbsp;from India. Supplies to the private market would be based upon receipt of market authorisation from ANVISA, the Brazilian regulatory authority.</p>

<p>India produces 60 per cent&nbsp;of global vaccines and amid the pandemic reaffirmed the position as the "Pharmacy of the world" by supplying HCQ and Paracetamol to 150 countries.&nbsp;</p>


As part of the globalisation of India-developed COVID-19 vaccine, India's Bharat Biotech has applied for "Emergency Use Authorization" (EUA) in the Philippines. EUA was filed earlier this month in the country and is the first international regulatory filing for Bharat biotech's COVAXIN.

As part of the globalisation of India-developed COVID-19 vaccine, India's Bharat Biotech has applied for "Emergency Use Authorization" (EUA) in the Philippines. EUA was filed earlier this month in the country and is the first international regulatory filing for Bharat biotech's COVAXIN. Once approved by the local regulator, India is expected to donate some doses and open the doors for exports in commercial terms, as are being done currently by Western and Chinese vaccine manufacturers. India's envoy to the Philippines Shambhu Kumaran in a tweet said, "A moment of pride for Indian R&D! The first international regulatory filing for COVAXIN. Delighted it is in the Philippines, a vital Indo-Pacific partner. Process ahead will be challenging but today we celebrate those who made this key milestone possible!" A moment of pride for #Indian R&D! The first international regulatory filing for COVAXIN. Delighted it is in #Philippines, a vital Indo-Pacific partner. Process ahead will be challenging but today we celebrate those who made this key milestone possible! @BharatBiotech @ICMRDELHI https://t.co/CNuclsSMJN — Shambhu Kumaran (@shambhukumaran) January 21, 2021 × The local drug regulatory authorities are looking for more clinical data from phase three trials and efficacy data. Phase III human clinical trials of COVAXIN began mid-November. The development is seen as a major step when it comes to India's vaccine exports and a boost to "Atmanirbhar Bharat" (Self-reliance). The EUA was applied as a part of "pro-active" action and an immediate approval will be issued as soon as the data comes. A delay in such action also means an impact on commercial deals in a very competitive coronavirus vaccine market. Interestingly, the Philippines already had a deal with Novavax for coronavirus vaccines for the supply of 30 million doses commercially. While India has so far exported India-made vaccines, the new frontier is seen when the export of India-developed vaccines becomes the norm. Meanwhile, Philippines foreign secretary Teodoro Locsin Jr has lauded India's vaccine diplomacy and, in a tweet, said, "we're looking to India to teach us. We're certainly not looking to the West. But we need to look elsewhere to teach us how to get it done" We’re looking to India to teach us. We’re certainly not looking to the West. But we need to look elsewhere to teach us how to get it done. https://t.co/yXLT3kOruk — Teddy Locsin Jr. (@teddyboylocsin) January 29, 2021 × New Delhi has gifted India-Made COVISHIELD vaccine of Oxford-AstraZeneca, made by Serum Institute of India, to 10 countries — Bhutan, Maldives, Nepal, Bangladesh, Myanmar, Seychelles, Mauritius, Sri Lanka, Bahrain and Oman. On Friday, Bangladesh's Foreign Secretary Ambassador Masud Bin Momen, speaking to WION, said Bharat Biotech has offered its vaccines to the country. Bangladesh is keen on the co-production of vaccines with India. Brazilian companies have also signed an agreement for the supply of COVAXIN from India. Supplies to the private market would be based upon receipt of market authorisation from ANVISA, the Brazilian regulatory authority. India produces 60 per cent of global vaccines and amid the pandemic reaffirmed the position as the "Pharmacy of the world" by supplying HCQ and Paracetamol to 150 countries.

With focus on globalization of India-developed vaccines, EUA for Covaxin filed in the Philippines

<p>The&nbsp;Haryana health minister Anil Vij has tested positive for the novel <a href="https://www.wionews.com/topics/coronavirus">coronavirus</a> after taking a trial shot of&nbsp;Bharat Biotech's Covaxin <a href="https://www.wionews.com/topics/coronavirus-vaccine">vaccine</a>.</p>

<p>"I have been tested Corona positive. I am admitted in Civil Hospital Ambala Cantt. All those who have come in close contact to me are advised to get themselves tested for corona," he posted on Twitter.</p>

<p><strong>Also read|&nbsp;<a href="https://www.wionews.com/india-news/india-adds-36652-new-coronavirus-cases-death-toll-stands-at-139700-347634" hreflang="en">India adds 36,652 new coronavirus cases; death toll stands at 139,700</a></strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">I have been tested Corona positive. I am admitted in Civil Hospital Ambala Cantt. All those who have come in close contact to me are advised to get themselves tested for corona.</p>
— ANIL VIJ MINISTER HARYANA (@anilvijminister) <a href="https://twitter.com/anilvijminister/status/1335093819654619137?ref_src=twsrc%5Etfw">December 5, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>Anil Vij, a&nbsp;Bharatiya Janata Party (BJP) leader, had taken a trial shot of India's COVID-19 vaccine's third phase of trial in Haryana on November 20. "I Will be administered trial dose of Coronavirus vaccine #Covaxin a Bharat Biotech product Tomorrow at 11 am at Civil Hospital, Ambala Cantt under the expert supervision of a team of &nbsp;Doctors from PGI Rohtak and Health Department. I have volunteered to take the trial dose," he had announced through Twitter.</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">I Will be administered trial dose of Coronavirus vaccine <a href="https://twitter.com/hashtag/Covaxin?src=hash&amp;ref_src=twsrc%5Etfw">#Covaxin</a> a Bharat Biotech product Tomorrow at 11 am at Civil Hospital, Ambala Cantt under the expert supervision of a team of Doctors from PGI Rohtak and Health Department. I have volunteered to take the trial dose.</p>
— ANIL VIJ MINISTER HARYANA (@anilvijminister) <a href="https://twitter.com/anilvijminister/status/1329393082614202369?ref_src=twsrc%5Etfw">November 19, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>A few weeks later when the minister was in Chandigarh, he reported fatigue and decided to get himself tested. "He got tested himself today morning and the result is positive. The staff will be tested today itself," his team had reported.</p>

<p>The news of him testing positive after administering a trial dose has raised questions about Bharat Biotech's vaccine's effectiveness.</p>

<p><strong>Also read|&nbsp;<a href="https://www.wionews.com/india-news/citing-tech-issues-un-covid-19-summit-nixes-adar-poonawalla-video-347619" hreflang="en">Citing tech issues, UN Covid-19 summit nixes Adar Poonawalla video</a></strong></p>

<p>Indian pharmaceutical company has also released a statement after Anil Vij tested positive. "Covaxin clinical trials are based on a 2-dose schedule, given 28 days apart. The vaccine efficacy will be determined 14 days post the 2nd dose. Covaxin has been designed to be efficacious when subjects receive both doses," the company said. "The phase-3 trials are double-blinded and randomized, where 50% of subjects (participants in the trial) receive vaccine &amp; 50% of subjects receive placebo."</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">COVAXINᵀᴹ trials are based on a 2-dose schedule, given 28 days apart. The vaccine efficacy will be determined 2 weeks after the 2nd dose. <a href="https://t.co/ZKmGuKbBMf">pic.twitter.com/ZKmGuKbBMf</a></p>
— BharatBiotech (@BharatBiotech) <a href="https://twitter.com/BharatBiotech/status/1335170865646850048?ref_src=twsrc%5Etfw">December 5, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>Bharat Biotech had started phase 3 trial of the vaccine only after successfully completing the trial of the first two phases. The pharmaceutical company has engaged with nearly 26,000 volunteers for this vaccine's third phase trial in India — making it the largest ever such trial in India.</p>


The Haryana health minister Anil Vij has tested positive for the novel coronavirus after taking a trial shot of Bharat Biotech's Covaxin vaccine. "I have been tested Corona positive.

The Haryana health minister Anil Vij has tested positive for the novel coronavirus after taking a trial shot of Bharat Biotech's Covaxin vaccine. "I have been tested Corona positive. I am admitted in Civil Hospital Ambala Cantt. All those who have come in close contact to me are advised to get themselves tested for corona," he posted on Twitter. Also read| India adds 36,652 new coronavirus cases; death toll stands at 139,700 I have been tested Corona positive. I am admitted in Civil Hospital Ambala Cantt. All those who have come in close contact to me are advised to get themselves tested for corona. — ANIL VIJ MINISTER HARYANA (@anilvijminister) December 5, 2020 × Anil Vij, a Bharatiya Janata Party (BJP) leader, had taken a trial shot of India's COVID-19 vaccine's third phase of trial in Haryana on November 20. "I Will be administered trial dose of Coronavirus vaccine #Covaxin a Bharat Biotech product Tomorrow at 11 am at Civil Hospital, Ambala Cantt under the expert supervision of a team of Doctors from PGI Rohtak and Health Department. I have volunteered to take the trial dose," he had announced through Twitter. I Will be administered trial dose of Coronavirus vaccine #Covaxin a Bharat Biotech product Tomorrow at 11 am at Civil Hospital, Ambala Cantt under the expert supervision of a team of Doctors from PGI Rohtak and Health Department. I have volunteered to take the trial dose. — ANIL VIJ MINISTER HARYANA (@anilvijminister) November 19, 2020 × A few weeks later when the minister was in Chandigarh, he reported fatigue and decided to get himself tested. "He got tested himself today morning and the result is positive. The staff will be tested today itself," his team had reported. The news of him testing positive after administering a trial dose has raised questions about Bharat Biotech's vaccine's effectiveness. Also read| Citing tech issues, UN Covid-19 summit nixes Adar Poonawalla video Indian pharmaceutical company has also released a statement after Anil Vij tested positive. "Covaxin clinical trials are based on a 2-dose schedule, given 28 days apart. The vaccine efficacy will be determined 14 days post the 2nd dose. Covaxin has been designed to be efficacious when subjects receive both doses," the company said. "The phase-3 trials are double-blinded and randomized, where 50% of subjects (participants in the trial) receive vaccine & 50% of subjects receive placebo." COVAXINᵀᴹ trials are based on a 2-dose schedule, given 28 days apart. The vaccine efficacy will be determined 2 weeks after the 2nd dose. pic.twitter.com/ZKmGuKbBMf — BharatBiotech (@BharatBiotech) December 5, 2020 × Bharat Biotech had started phase 3 trial of the vaccine only after successfully completing the trial of the first two phases. The pharmaceutical company has engaged with nearly 26,000 volunteers for this vaccine's third phase trial in India — making it the largest ever such trial in India.

Haryana minister Anil Vij tests positive for COVID-19 after trial Covaxin shot

covaxin-vaccine

Covaxin Vaccine, News on Covaxin Vaccine, stories on Covaxin Vaccine, articles on Covaxin Vaccine, Covaxin Vaccine stories at Wion, Covaxin Vaccine news, Covaxin Vaccine latest news

covaxin vaccine

India: Covaxin yet to get DCGI nod for kids

Gravitas: India to begin Covaxin vaccine trials for kids

India: Production capacity of Covaxin to be doubled by May-June 2021

With focus on globalization of India-developed vaccines, EUA for Covaxin filed in the Philippines

Haryana minister Anil Vij tests positive for COVID-19 after trial Covaxin shot